Diabetes: A Disease of Epidemic Proportions²

The world is battling diabetes. AstraZeneca’s ambition is to be a leader in that fight.

What Is Diabetes?

- Occurs when the body has insufficient insulin production or is unable to respond to its effects¹
- People with type-2 diabetes can remain undiagnosed for many years, unaware of the long-term damage being caused²
- This can lead to a build-up of glucose in the blood [hyperglycaemia]¹
- Significant unmet needs exist as many patients remain uncontrolled on their current treatment regimen³
- Type 2 diabetes is the most commonly diagnosed form of diabetes²
- If untreated, diabetes can lead to serious complications & early death²

The Global Diabetes Burden

Incidence of type 2 diabetes is increasing across the globe²

- 425 million people, or 8.8% of adults 20-79 years worldwide are estimated to have diabetes
- 79% of people with diabetes live in low and middle income countries²
- Type 2 diabetes accounts for around 90% of all diagnosed cases of diabetes²
- Diabetes is projected to affect up to 629 million people by 2045²
- 30-80% of people with diabetes remain undiagnosed²
- Demand is rising for treatments that meet individual patient needs²

AstraZeneca & Diabetes

Seeking to positively impact the lives of patients to help reduce the disease burden and its complications

First company to offer products in all three of the newest, fastest-growing classes of type 2 diabetes treatments:
- SGLT2 inhibitors
- GLP-1 receptor agonists
- DPP-4 inhibitors

Focused on advancing the treatment paradigm to use combination therapies to help more patients achieve their treatment goals⁴

Committed to:

- Ushering in a new era of innovative diabetes care
- Pursuing scientific excellence to address patients’ unmet needs
- Investing in R&D that may help discover novel treatment pathways
- Offering individualised approaches to care

⁴. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 2009;58(714).

For media use - please obtain local nominated signatory approval before use.